Ascendis Pharma AS (NASDAQ:ASND)’s share price rose 11.9% during mid-day trading on Tuesday . The stock traded as high as $17.27 and last traded at $17.07, with a volume of 126,918 shares changing hands. The stock had previously closed at $15.25.

ASND has been the topic of several recent research reports. Zacks Investment Research cut Ascendis Pharma AS from a “hold” rating to a “sell” rating in a research report on Tuesday, May 24th. Leerink Swann reiterated an “outperform” rating and set a $24.00 target price on shares of Ascendis Pharma AS in a research report on Thursday, May 26th.

The firm’s market cap is $428.93 million. The stock has a 50-day moving average of $13.67 and a 200-day moving average of $15.84.

Ascendis Pharma AS (NASDAQ:ASND) last posted its quarterly earnings data on Friday, May 20th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by $0.37. On average, equities analysts forecast that Ascendis Pharma AS will post ($3.31) earnings per share for the current fiscal year.

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.